LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Cerrado

SectorSanidad

54.33 -2.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

54.1

Máximo

55.38

Métricas clave
By Trading Economics
Ingresos	3M -102M
BPA	-1.17
Empleados	358
EBITDA	-7.6M -112M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+39.95% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-155M 5.4B
Apertura anterior	57.26
Cierre anterior	54.33

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

88 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

34.81 / 38.24 Soporte y Resistencia

Xenon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 mar 2026, 16:12 UTC

Principales Movimientos del Mercado

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

39.95% repunte

Estimación a 12 Meses

Media 78.37 USD 39.95%

Máximo 100 USD

Mínimo 55 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

88 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.